Canadian company Biovail Corp says that Canada's Therapeutic ProductsDirectorate has granted marketing authorization for its Tiazac XC (diltiazem hydrochloride) for the treatment of hypertension. The firm plans to launch the product in the first quarter of next year.
Tiazac XC combines Biovail's drug delivery technology with the well-established efficacy of the calcium channel blocker, diltiazem, which has been used as an anti-hypertensive in Canada for more than 20 years.
Targets high-risk morning surge in BP
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze